Linda Huber uses her biochemistry background and patent experience to represent medical and academic institutions, private foundations and medical device and pharmaceutical companies in intellectual property matters.
I focus on prosecuting biotechnology and life sciences patents, counseling clients on their patent portfolios and prosecution strategies, conducting due diligence of patent portfolios in corporate transactions and patent license agreements and advising clients on patent related license provisions.
Particular areas I focus on include cancer therapeutics, gene therapy, stem cells, gastrointestinal diseases, inflammatory conditions, neurological diseases, diagnostics and nutritional products.
Through my understanding of my clients’ needs and goals, I develop and implement strategies to manage and expand their patent portfolios. I also help them understand the implications of licensing terms.
I believe that the Federal Circuit will refine the definition of patent-eligible subject matter in favor of patentees.
Law360 | April 28, 2017
This article mentions recent leadership promotions at the firm including David Brown, Jared Lusk, Jim Vallee, Graham Beck, Kathleen Ceglarski Burns, Emily Crandall Harlan, Daniel Gibbons, Linda Huber, Ilana Kameros, Haydon Keitner, Darren Miller, Neal Pandozzi, Edward Puerta, Stephen Reil, and Elizabeth Young.